{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:25:19Z","timestamp":1793993119406,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma (RR-ENKTL), however, the complete response (CR) rate and the duration of response (DOR) need to be improved. This phase 1b\/2 study investigated the safety and efficacy of sintilimab, a fully human anti-PD-1 antibody, plus chidamide, an oral subtype-selective histone deacetylase inhibitor in 38 patients with RR-ENKTL. Expected objective response rate (ORR) of combination treatment was 80%. Patients received escalating doses of chidamide, administered concomitantly with fixed-dose sintilimab in 21-days cycles up to 12 months. No dose-limiting events were observed, RP2D of chidamide was 30\u2009mg twice a week. Twenty-nine patients were enrolled in phase 2. In the intention-to-treat population (n\u2009=\u200937), overall response rate was 59.5% with a complete remission rate of 48.6%. The median DOR, progression-free survival (PFS), and overall survival (OS) were 25.3, 23.2, and 32.9 months, respectively. The most common grade 3 or higher treatment-emergent adverse events (AEs) were neutropenia (28.9%) and thrombocytopenia (10.5%), immune-related AEs were reported in 18 (47.3%) patients. Exploratory biomarker assessment suggested that a combination of dynamic plasma ctDNA and EBV-DNA played a vital prognostic role. STAT3 mutation shows an unfavorable prognosis. Although outcome of anticipate ORR was not achieved, sintilimab plus chidamide was shown to have a manageable safety profile and yielded encouraging CR rate and DOR in RR-ENKTL for the first time. It is a promising therapeutic option for this population.<\/jats:p>","DOI":"10.1038\/s41392-024-01825-0","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T20:02:03Z","timestamp":1715889723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib\/II study"],"prefix":"10.1038","volume":"9","author":[{"given":"Yan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-7477","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-3282","authenticated-orcid":false,"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-9917","authenticated-orcid":false,"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Jibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baitian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"1825_CR1","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/cancers13061414","volume":"13","author":"IA Montes-Mojarro","year":"2021","unstructured":"Montes-Mojarro, I. A., Fend, F. & Quintanilla-Martinez, L. EBV and the pathogenesis of NK\/T cell lymphoma. Cancers 13, 1414 (2021).","journal-title":"Cancers"},{"key":"1825_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun, J. et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am. J. Clin. Pathol. 138, 429\u2013434 (2012).","journal-title":"Am. J. Clin. Pathol."},{"key":"1825_CR3","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3026(19)30283-2","volume":"7","author":"CP Fox","year":"2020","unstructured":"Fox, C. P. et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 7, e284\u2013e294 (2020).","journal-title":"Lancet Haematol."},{"key":"1825_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","volume":"17","author":"SJ Kim","year":"2016","unstructured":"Kim, S. J. et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 17, 389\u2013400 (2016).","journal-title":"Lancet Oncol."},{"key":"1825_CR5","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","volume":"28","author":"SH Lim","year":"2017","unstructured":"Lim, S. H. et al. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann. Oncol. 28, 2199\u20132205 (2017).","journal-title":"Ann. Oncol."},{"key":"1825_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","volume":"35","author":"M Yamaguchi","year":"2017","unstructured":"Yamaguchi, M. et al. Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J. Clin. Oncol. 35, 32\u201339 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1825_CR7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(16)30148-6","volume":"17","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 17, 1240\u20131247 (2016).","journal-title":"Lancet Oncol."},{"key":"1825_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong, J. et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell 37, 403\u2013419.e6 (2020).","journal-title":"Cancer Cell"},{"key":"1825_CR9","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"Y-L Kwong","year":"2017","unstructured":"Kwong, Y.-L. et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood 129, 2437\u20132442 (2017).","journal-title":"Blood"},{"key":"1825_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","volume":"6","author":"R Tao","year":"2021","unstructured":"Tao, R. et al. Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct. Target. Ther. 6, 365 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1825_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J. Hematol. Oncol. 14, 12 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"1825_CR12","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood.2020007247","volume":"136","author":"SJ Kim","year":"2020","unstructured":"Kim, S. J. et al. Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study. Blood 136, 2754\u20132763 (2020).","journal-title":"Blood"},{"key":"1825_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper, M. J. et al. The emerging role of epigenetic therapeutics in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 75\u201390 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1825_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi, Y. et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26, 1766\u20131771 (2015).","journal-title":"Ann Oncol"},{"key":"1825_CR15","first-page":"2797","volume":"130","author":"G Yan","year":"2017","unstructured":"Yan, G. et al. Chidamide, oral subtype-selective histone deacetylase inhibitor (HDACI) monotherapy was effective on the patients with relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma. Blood 130, 2797\u20132797 (2017).","journal-title":"Blood"},{"key":"1825_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01436-6","volume":"15","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK\/T-cell lymphoma to chidamide. Clin. Epigenetics 15, 19 (2023).","journal-title":"Clin. Epigenetics"},{"key":"1825_CR17","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","volume":"22","author":"H Zheng","year":"2016","unstructured":"Zheng, H. et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 22, 4119\u20134132 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1825_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104420","volume":"87","author":"T Wen","year":"2023","unstructured":"Wen, T. et al. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-gamma response in NK-T cell lymphoma. EBioMedicine 87, 104420 (2023).","journal-title":"EBioMedicine"},{"key":"1825_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/14737140.2021.1853531","volume":"21","author":"Q Rong","year":"2021","unstructured":"Rong, Q. et al. High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural\/killer T-cell lymphoma (ENKTL). Expert Rev. Anticancer Ther. 21, 121\u2013127 (2021).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1825_CR20","first-page":"2589","volume":"8","author":"H Wang","year":"2015","unstructured":"Wang, H. et al. Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer\/T-cell lymphoma patients receiving asparaginase-based chemotherapy. Onco Targets Ther. 8, 2589\u20132599 (2015).","journal-title":"Onco Targets Ther."},{"key":"1825_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0723-4","volume":"30","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. Clinical significance of serum soluble interleukin-2 receptor-alpha in extranodal natural killer\/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. Med. Oncol. 30, 723 (2013).","journal-title":"Med. Oncol."},{"key":"1825_CR22","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat, S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin. Cancer Res. 23, 1920\u20131928 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1825_CR23","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin, A. M. et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J. Clin. Oncol. 34, 2698\u20132704, (2016).","journal-title":"J. Clin. Oncol."},{"key":"1825_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-143252","volume":"136","author":"SP Iyer","year":"2020","unstructured":"Iyer, S. P. et al. A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL). Blood 136, 40\u201341 (2020).","journal-title":"Blood"},{"key":"1825_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","volume":"552","author":"T Wartewig","year":"2017","unstructured":"Wartewig, T. et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552, 121\u2013125 (2017).","journal-title":"Nature"},{"key":"1825_CR26","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1182\/blood.2019002038","volume":"134","author":"DA Rauch","year":"2019","unstructured":"Rauch, D. A. et al. Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood 134, 1406\u20131414 (2019).","journal-title":"Blood"},{"key":"1825_CR27","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes, A. et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann. Oncol. 28, 1436\u20131447 (2017).","journal-title":"Ann. Oncol."},{"key":"1825_CR28","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1825_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control. Clin. Trials"},{"key":"1825_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/biostatistics\/kxs043","volume":"14","author":"EP Wileyto","year":"2013","unstructured":"Wileyto, E. P., Li, Y., Chen, J. & Heitjan, D. F. Assessing the fit of parametric cure models. Biostatistics 14, 340\u2013350 (2013).","journal-title":"Biostatistics"},{"key":"1825_CR31","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2022.40.16_suppl.7501","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang, H. et al. GEMSTONE-201: preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer\/T cell lymphoma (R\/R ENKTL). J. Clin. Oncol. 40, 7501\u20137501 (2022).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01825-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01825-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01825-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T20:02:10Z","timestamp":1715889730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01825-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-01825-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"26 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}